Olokizumab in patients with inflammatory phenotype of osteoarthritis, treatment experience

QR Code

Olokizumab in patients with inflammatory phenotype of osteoarthritis, treatment experience

Objective: to investigate the efficacy and safety of olokizumab (OKZ) in patients with knee osteoarthritis (OA) with synovitis, persistent pain and ineffectiveness of previous conservative therapy. Material and methods. The study included 15 patients with stage II–III knee OA who fulfilled the ACR...

Full description

Saved in:

Bibliographic Details
Main Authors:	A. M. Lila, L. I. Alekseeva, E. A. Taskina, N. G. Kashevarova, E. P. Sharapova, E. A. Strebkova, N. M. Savushkina, A. R. Khalmetova, V. A. Nesterenko, A. S. Avdeeva, E. Yu. Samarkina, M. E. Diatroptov, O. G. Alekseeva
Format:	Article
Language:	Russian
Published:	IMA-PRESS LLC 2024-06-01
Series:	Современная ревматология
Subjects:	osteoarthritis inflammatory phenotype interleukin 6 olokizumab
Online Access:	https://mrj.ima-press.net/mrj/article/view/1584
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Clinical case of olokizumab treatment in a patient with diffuse systemic sclerosis
by: E. S. Kuvardin, et al.
Published: (2022-11-01)

Current approaches to osteoarthritis phenotyping
by: A. M. Lila, et al.
Published: (2019-05-01)

Efficacy of olokizumab against comorbid depressive disorder in patients with rheumatoid arthritis: Preliminary results of the study
by: T. A. Lisitsyna, et al.
Published: (2023-04-01)

Efficacy and safety of olokizumab in the treatment of rheumatoid arthritis in real-world clinical practice in Kazakhstan
by: G. A. Togizbayev, et al.
Published: (2025-06-01)

The prospects of interleukin-6 inhibition in rheumatoid arthritis: Olokizumab (novel monoclonal antibodies to IL-6)
by: E. L. Nasonov, et al.
Published: (2022-11-01)

Experience with olokizumab in the treatment of polymyalgia rheumatica and giant cell arteritis: A series of cases
by: Alexey D. Meshkov, et al.
Published: (2024-09-01)

Factors associated with knee pain at early stages of osteoarthritis
by: A. R. Khalmetova, et al.
Published: (2025-06-01)

Experience of using the interleukin-6 inhibitor olokizumab in patients with rheumatoid arthritis in real-life clinical practice (based on data from Tyumen Regional Rheumatology Center)
by: I. M. Patrikeeva, et al.
Published: (2025-02-01)

A prospective study on the effects of glucosamine hydrochloride and chondroitin sulfate combination on systemic inflammation markers in patients with knee osteoarthritis (report 1)
by: A. M. Lila, et al.
Published: (2025-06-01)

Osteoarthritis of hand joints: prevalence, risk factors, phenotypes, diagnosis, treatment
by: L. I Alekseeva, et al.
Published: (2022-12-01)

Dynamics of clinical manifestations and cytokine concentrations in patients with rheumatoid arthritis on olokizumab therapy
by: N. A. Lapkina, et al.
Published: (2023-08-01)

CHARACTERISTICS OF OLOKIZUMAB PHARMACOKINETICS IN PATIENTS WITH NOVEL CORONAVIRUS INFECTION COVID-19
by: E. V. Tavlueva, et al.
Published: (2022-12-01)

Efficacy and safety of diacerein in patients with knee osteoarthritis
by: L. I. Alekseeva, et al.
Published: (2017-09-01)

Modern achievements in pharmacotherapy of osteoarthritis based on endo- and phenotyping
by: I. V. Sarvilina, et al.
Published: (2021-10-01)

Investigation of the analgesic efficacy of local therapy with non-steroidal anti-inflammatory drugs in patients with knee osteoarthritis
by: E. A. Strebkova, et al.
Published: (2024-10-01)

Clinical and instrumental characteristics of osteoarthritis in hyperuricemia
by: E. A. Taskina, et al.
Published: (2024-10-01)

Switching from interleukin-6 receptor inhibitors to the direct interleukin-6 inhibitor olokizumab in patients with rheumatoid arthritis: efficacy and safety during one year of therapy
by: P. A. Shesternya, et al.
Published: (2024-10-01)

Multimorbidity in osteoarthritis
by: E. A. Taskina, et al.
Published: (2022-07-01)

Relationship between vitamin D and osteoarthritis
by: Natalia G. Kashevarova, et al.
Published: (2025-01-01)

OSTEOARTHRITIS AND OBESITY
by: E. A. Strebkova, et al.
Published: (2015-10-01)

Osteoarthritis as an interdisciplinary problem: treatment algorithm for physicians and general practitioners
by: A. M. Lila, et al.
Published: (2021-10-01)

A prospective comparative randomized trial of the efficacy and safety of topical tenoxicam and diclofenac in knee osteoarthritis
by: N. G. Kashevarova, et al.
Published: (2023-07-01)

Efficacy of Chondroitin Sulfate in Patients with Knee and Hip Osteoarthritis
by: E. P. Sharapova, et al.
Published: (2021-08-01)

Use of olokizumab, a direct interleukin 6 inhibitor, in the treatment of rheumatoid arthritis: real-world evidence
by: P. A. Shesternya, et al.
Published: (2025-04-01)

The place of nonsteroidal anti-inflammatory drugs in the current osteoarthritis guidelines
by: E. A. Taskina, et al.
Published: (2020-05-01)

Long-term multicenter observational study of the drug Alflutop in Russia: use in patients with knee osteoarthritis (report 4)
by: E. A. Taskina, et al.
Published: (2024-08-01)

The influence of type 2 diabetes mellitus on clinical manifestations of osteoarthritis
by: E. A. Taskina, et al.
Published: (2024-08-01)

Evaluation of the combination of glucosamine and chondroitin sulfate supplemented with native (non-denatured) type II collagen, ginger extract, B vitamins and ascorbic acid effect on the clinical manifestations of OA in patients with various phenotypes of the disease (preliminary results)
by: A. M. Lila, et al.
Published: (2024-12-01)

KNEE OSTEOARTHRITIS AND METABOLIC SYNDROME: NEW APPROACHES TO THERAPY
by: L. I. Alekseeva, et al.
Published: (2018-05-01)

Osteoarthritis: modern aspects of pathogenesis, focus on low-intensity inflammation
by: I. S. Svintsitskaya, et al.
Published: (2025-04-01)

Results of a 12-week open-label, non-interventional study of the efficacy and safety of olokizumab therapy in patients with rheumatoid arthritis after switching from anti-B-cell therapy during the SARS-CoV-2 pandemic
by: A. A. Akimova, et al.
Published: (2023-03-01)

Results of a 24-week open-label, non-interventional study on the efficacy and safety of olokizumab therapy in patients with rheumatoid arthritis after switching from anti-B-cell therapy during the SARS-CoV-2 pandemic
by: A. V. Fedorova, et al.
Published: (2024-06-01)

Ultrasound Phenotype-Based Approach to Treatment Choice in Osteoarthritis
by: Rositsa Karalilova, et al.
Published: (2025-07-01)

Multicenter Longitudinal Observational Study Pharmaceuticals Alflutop in Russia (message 2)
by: A. M. Lila, et al.
Published: (2023-08-01)

Management of patients with rheumatoid arthritis in real clinical practice: Switching from interleukin 6 receptor inhibitors to interleukin 6 inhibitor (olokizumab)
by: A. A. Baranov, et al.
Published: (2023-06-01)

Expression of genes related to glucose metabolism and joint destruction in the development of diabetes mellitus in patients with osteoarthritis
by: E. V. Chetina, et al.
Published: (2019-03-01)

Diacerein in the treatment of osteoarthritis in patients with comorbidity
by: E. P. Sharapova, et al.
Published: (2018-12-01)

Effect of interleukin 6 blockers on body composition, adipocytokines and insulin-like growth factor 1 in patients with rheumatoid arthritis
by: L. V. Kondratyeva, et al.
Published: (2025-07-01)

Experience with the interleukin 6 inhibitor (Olokizumab) in patients with rheumatoid arthritis in real clinical practice: Influence on inflammatory activity and disease outcomes
by: N. A. Lapkina, et al.
Published: (2023-10-01)

Osteoarthritis: epidemiology, classification, risk factors, and progression, clinical presentation, diagnosis, and treatment
by: L. I. Alekseeva, et al.
Published: (2019-05-01)